The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
Br J Cancer
; 82(1): 81-4, 2000 Jan.
Article
em En
| MEDLINE
| ID: mdl-10638970
ABSTRACT
As part of an NHS Executive Trent regional initiative we considered the role and cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. The key trials and case series show an additional patient benefit of 0.8-1.1 life years over standard chemotherapy. We estimate incremental cost per life year gained of 12 800 pound silver-17 600 pound silver, which reduces further if long-term benefits are considered. High dose chemotherapy in these conditions is both life-saving and cost-effective.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfoma não Hodgkin
/
Doença de Hodgkin
/
Terapia de Salvação
/
Antineoplásicos
Tipo de estudo:
Diagnostic_studies
/
Health_economic_evaluation
/
Systematic_reviews
Limite:
Humans
Idioma:
En
Revista:
Br J Cancer
Ano de publicação:
2000
Tipo de documento:
Article
País de afiliação:
Reino Unido